Clinical trial shows significant disease-free survival for patients diagnosed with non-small cell lung cancer
New data from a Yale Cancer Center-led clinical trial shows improved rates of survival and reduced risk of recurrence in patients taking osimertinib, a targeted therapy for non-small cell lung cancer (NSCLC). NSCLC is the ...
Jan 31, 2023
0
21